You are here: Industry Insights > Novartis

News List

Novartis and Bayer seek to oppose High Court ruling over NHS decision to use cheaper drug pharmafile
October 19, 2018
Swiss multinational Novartis have joined German pharma firm Bayer in appealing a High Court ruling over 12 NHS clinical commissioning groups (CCGs) decision to use a cheaper...
Merck joins Novartis, GlaxoSmithKline in grabbing a consumer executive to beef up digital fiercepharma
October 19, 2018
Merck joins Novartis, GlaxoSmithKline in grabbing a consumer executive to beef up digital
Novartis snaps up cancer drug developer Endocyte for $2.1 billion pharmafile
October 19, 2018
Novartis will shell out $2.1 billion to acquire cancer drug developer Endocyte in a move to leverage the company’s technology to investigate potential development of therapies in prostate cancer, it has emerged.
Novartis buys Endocyte for $2.1 billion pharmatimes
October 19, 2018
Novartis has signed a deal to acquire US biopharma Endocyte, securing itself access to novel radiopharmaceutical programmes “with significant sales potential”.
NHS green light for Novartis skin cancer combo pharmatimes
October 19, 2018
The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available to eligible skin cancer patients, after cost regulators published guidance backing funds for the treatment.
Amgen, Novartis first to launch Humira biosimilars in Europe biospectrumasia
October 17, 2018
Tags: Top Story Amgevita Humira Hyrimoz AbbVie Amgen Novartis Arthritis IBD Psoriasis General Practice Internal Medicine Marketing & Sales
Novartis, Pfizer, AZ and more hand China 50%-plus cancer drug discounts fiercepharma
October 11, 2018
China is quickly approving many of the newest cancer drugs but it also is demanding big discounts if drugmakers want them on its national insurance coverage list.
Novartis files MS drug siponimod in EU and US pharmatimes
October 11, 2018
Novartis is seeking approval on both sides of the Atlantic for use of experimental multiple sclerosis therapy siponimod to treat secondary progressive forms of the disease.
Novartis crizanlizumab shows promise in sickle cell anaemia pharmatimes
October 11, 2018
A new analysis has shown that Novartis’ crizanlizumab reduced the number of patients with sickle cell disease experiencing a pain crisis.
Novartis Licenses Three Novel Anti-Infective Programs to Boston Pharmaceuticals americanpharmaceuticalreview
October 08, 2018
Novartis has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates that are part of the Novartis Infectious Diseases portfolio...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page